Parkinsonism & Related Disorders
Volume 16, Issue 2 , Pages 142-145, February 2010

Consecutive analyses of cerebrospinal fluid axonal and glial markers in Parkinson's disease and atypical parkinsonian disorders☆

  • Radu Constantinescu

      Affiliations

    • Department of Neurology, Sahlgrenska University Hospital, 413 45 Göteborg, Sweden
    • Corresponding Author InformationCorresponding author. Tel.: +46 31 3421000.
    • ,
  • Lars Rosengren

      Affiliations

    • Department of Neurology, Sahlgrenska University Hospital, 413 45 Göteborg, Sweden
    • ,
  • Bo Johnels

      Affiliations

    • Department of Neurology, Sahlgrenska University Hospital, 413 45 Göteborg, Sweden
    • ,
  • Henrik Zetterberg

      Affiliations

    • Department of Psychiatry and Neurochemistry, Sahlgrenska University Hospital, 431 80 Mölndal, Sweden
    • ,
  • Bjorn Holmberg

      Affiliations

    • Department of Neurology, Sahlgrenska University Hospital, 413 45 Göteborg, Sweden

Received 16 November 2008; received in revised form 23 June 2009; accepted 15 July 2009.

Abstract 

Cerebrospinal fluid (CSF) levels of neurofilament light protein (NFL), a marker of neuronal damage, are normal in Parkinson's disease (PD) but elevated in multiple system atrophy (MSA) and progressive supranuclear palsy (PSP). Therefore, CSF NFL can help differentiate between PD on one hand and MSA/PSP on the other. In the present study of 10 patients with PD, 21 with MSA, 14 with PSP, 11 with corticobasal degeneration (CBD), and 59 healthy controls, this previous observation is confirmed and also extended to include CBD by showing that similarly high CSF NFL levels are seen not only in MSA and PSP but also in CBD. CSF levels of glial fibrillary acidic protein (GFAP), a protein expressed mainly in fibrillary astrocytes, were similar in all investigated groups. In addition, consecutive analyses of CSF NFL and CSF GFAP levels showed relatively stable levels over time in all the investigated parkinsonian disorders, suggesting that the rate of neuronal degeneration is rather constant over time. Our results suggest that measurements of CSF NFL but not GFAP can be useful in the differential diagnosis of PD versus atypical parkinsonian disorders (APD). However they do not help differentiate between the different APD.

Keywords: Neurofilament triplet protein, Glial fibrillary acidic protein, Cerebrospinal fluid, Parkinsonian disorders, Brain related proteins

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

☆ The review of this paper was entirely handled by an Associate Editor, Vincenzo Bonifati.

PII: S1353-8020(09)00196-5

doi:10.1016/j.parkreldis.2009.07.007

Parkinsonism & Related Disorders
Volume 16, Issue 2 , Pages 142-145, February 2010

Article Tools

* Image Usage & Resolution